MDM2 and ovarian carcinoma: In conclusion, in this study, we found that miR-194-5p loss is deeply involved in acquired resistance to paclitaxel and restoring miR-194-5p expression attenuates paclitaxel resistance by targeting MDM2 in ovarian cancer cells.